CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY

In patients with well-differentiated thyroid cancer (WDTC) recurrence the metastatic tumor foci in numerous cases are not responded to radioiodine therapy which seriously deteriorate survival prognosis. In this article the contemporary evidential basis is analyzed so as to determine criteria of the...

Full description

Saved in:

Bibliographic Details
Main Authors:	P. O. Rumyantsev, D. K. Fomin, U. V. Rumyantseva
Format:	Article
Language:	Russian
Published:	ABV-press 2015-04-01
Series:	Опухоли головы и шеи
Subjects:	thyroid cancer radioiodine therapy radioiodine-resistant metastases multikinase inhibitors sorafenib
Online Access:	https://ogsh.abvpress.ru/jour/article/view/78
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Radioiodine-resistant metastases of well-differentiated thyroid cancer, analysis of tumor characteristics and primary surgical intervention
by: M. V. Ostafiychuk, et al.
Published: (2021-10-01)

Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors
by: Suset Dueñas-Disotuar, et al.
Published: (2024-11-01)

Brain metastasis from differentiated thyroid carcinoma responding to radioiodine therapy
by: Leo Hashimoto, et al.
Published: (2025-07-01)

Experience in the use of targeted therapy in patients with radio-resistant forms of thyroid cancer in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
by: E. B. Vasil’eva, et al.
Published: (2018-04-01)

Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up
by: A. Yu. Shurinov, et al.
Published: (2024-06-01)

Effectiveness of radioiodine therapy on preventing recurrence in differentiated thyroid carcinoma: a systematic review
by: Bima Indra, et al.
Published: (2025-05-01)

Clinical outcome and influencing factors of differentiated thyroid cancer patients with radioiodine-refractory lung metastasis
by: Congcong Wang, et al.
Published: (2025-08-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

A rare case of minimally invasive follicular thyroid cancer with intraluminal superior vena cava and right atrium metastases
by: Alex Cheen Hoe Khoo, et al.
Published: (2019-07-01)

A practical approach on radioprotection in the treatment of radioiodine for thyroid cancer
by: Janaína Dutra Silvestre Mendes, et al.
Published: (2018-09-01)

Low risk of thyroid eye disease (TED) following radioiodine (RAI) therapy in a multidisciplinary setting: a retrospective cohort study
by: John S. Vekinis, et al.
Published: (2025-08-01)

Comparison of radioiodine ablation rates between low versus high dose, and according to the surgeon's expertise in the low-risk group of differentiated thyroid cancer
by: Ghazal Norouzi, et al.
Published: (2021-03-01)

Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
by: P. O. Rumyantsev, et al.
Published: (2021-11-01)

Low-Dose Versus Standard-Dose Radioiodine Therapy in Differentiated Thyroid Cancer: Focus on Tolerability in a Retrospective Evaluation
by: Laura Musso, et al.
Published: (2025-03-01)

Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness
by: E. V. Borodavina, et al.
Published: (2024-08-01)

RADIOIODINE THERAPY OF PAPILLARY THYROID CANCER, COMPLICATED BY A RADIAL MYELITIS. CLINICAL CASE
by: L. M. Farkhutdinova
Published: (2018-06-01)

Pleural metastases from differentiated thyroid cancer: clinical features and long-term outcomes
by: Mengyue Liu, et al.
Published: (2025-01-01)

Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer
by: Jan Taprogge, et al.
Published: (2025-07-01)

Radioiodine Thyroid Ablation in Graves′ Hyperthyroidism: Merits and Pitfalls
by: J. Nwatsock, et al.
Published: (2012-01-01)

Gastrointestinal side effects of the radioiodine therapy for the patients with differentiated thyroid carcinoma two days after prescription
by: Mehran Pashnehsaz, et al.
Published: (2016-07-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

REFRACTORY OF WELL-DIFFERENTIATED THYROID CANCER TO THE TREATMENT WITH RADIOACTIVE IODINE
by: P. O. Rumyantsev
Published: (2015-04-01)

Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study)
by: Giulia Puliani, et al.
Published: (2025-04-01)

Radioiodine (131I) therapy in a child with autism spectrum disorder: A complex and demanding task
by: Giovanni Bibbo, et al.
Published: (2019-07-01)

Management of radioiodine ablation therapy in haemodialysis patients with thyroid cancer: a case series of two patients
by: Raymond Lin, et al.
Published: (2025-07-01)

The Impact of Radioiodine (131I) Therapy of Thyroid Disease on Salivary Glands Function and Inflammation: A Comprehensive Review
by: Pietro Bellini, et al.
Published: (2025-06-01)

Differentiated thyroid cancer in two European referral centres: impact of different diagnostic and therapeutic strategies
by: Daniele Ceruti, et al.
Published: (2025-08-01)

“Tumour sink effect” on the diagnostic or posttreatment radioiodine scan due to sequestration into large-volume functioning metastasis of differentiated thyroid carcinoma influencing uptake in smaller metastatic sites or remnant thyroid tissue: An uncommon but possible phenomenon in thyroid cancer practice
by: Sandip Basu, et al.
Published: (2020-04-01)

Selpercatinib in the treatment of medullary and radioiodine-refractory differentiated thyroid cancer with RET mutation (literature review)
by: E. V. Borodavina, et al.
Published: (2025-03-01)

Neoadjuvant target therapy of differentiated thyroid cancer (clinical observation)
by: P. A. Isaev, et al.
Published: (2017-04-01)

Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
by: E. V. Borodavina, et al.
Published: (2024-12-01)

Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy
by: E. V. Borodavina, et al.
Published: (2022-02-01)

THE USE OF SORAFENIB (NEXAVAR) IN TREATMENT OF PATIENT WITH DISSEMINATED PARATHYROID CANCER: A CASE REPORT
by: V. A. Gorbunova, et al.
Published: (2017-04-01)

Effect of Presence of Uni- or Bilateral Thyroid Adenoma on Recovery of Pituitary–Thyroid Axis and Creatinine Concentration in Radioiodine-Treated Cats
by: Anna Paulina Menzel, et al.
Published: (2024-09-01)

Determination of Organ Doses in Radioiodine Therapy using Monte Carlo Simulation
by: Daryoush Shahbazi-Gahrouei, et al.
Published: (2015-01-01)

Complete remission of peritoneal strumosis from struma ovarii after radioiodine therapy: a case report
by: Jun Yang, et al.
Published: (2025-06-01)

Outcomes following I-131 treatment with cumulative dose exceeding or equal to 600 mCi in differentiated thyroid carcinoma patients
by: Chalermrat Kaewput, et al.
Published: (2021-03-01)

Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience
by: David J. Lubin, et al.
Published: (2021-07-01)

Outcome of Radioiodine Therapy in a West African Population
by: Yetunde Onimode, et al.
Published: (2016-01-01)

Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
by: F. S. Sevryukov, et al.
Published: (2021-01-01)